Citation Impact
Citing Papers
p53: puzzle and paradigm.
1996 Standout
Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
2000
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
2000
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma
2003 StandoutNobel
The Cellular Basis of Tumor Progression
1997
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines
2000
The third dimension bridges the gap between cell culture and live tissue
2007 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Expression of hypoxia-inducible factor 1: mechanisms and consequences
2000 StandoutNobel
Cisplatin resistance in human cancers
1991
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
2012 StandoutNobel
In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines
1992
Contrasting cellular uptake pathways for chlorido and iodido iminopyridine ruthenium arene anticancer complexes
2012
cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines
1996
Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels
1991
Drug penetration in solid tumours
2006 Standout
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes
1992
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
2014
The resurgence of platinum-based cancer chemotherapy
2007 Standout
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
1998
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties
2004
Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance
2006
New Cisplatin Analogues in Development
1993
Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin
1993
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels
1996
Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study
1992
Preclinical Perspectives on Platinum Resistance
2000
Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines
1991
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer
2013 StandoutNobel
Chemotherapy and the war on cancer
2005 Standout
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
1995
Cellular processing of platinum anticancer drugs
2005 Standout
High interstitial fluid pressure — an obstacle in cancer therapy
2004 Standout
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
1991
“Of mice and men”
2004
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
2000
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
Targeting gene expression to hypoxic tumor cells
1997 StandoutNobel
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
2003
Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET
2000
Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line
1996 StandoutNobel
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors
2002 StandoutNobel
Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells
1994
Vascularization and curability of stage III and IV nasopharyngeal tumors
1988
Oncogenic alterations of metabolism
1999 StandoutNobel
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
1993
New platinum antitumor complexes
1993
Cancer as an evolutionary and ecological process
2006 Standout
Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors
2000
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
2004
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
1993
DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines
1995
Current status of the development of trans-platinum antitumor drugs
2000
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma
2004
Tumor subpopulation interactions in neoplasms
1983
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Disulfiram Facilitates Intracellular Cu Uptake and Induces Apoptosis in Human Melanoma Cells
2004
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
1995
Tumor vascularity: a histological measure of angiogenesis and hypoxia.
2001
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient
1987
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Synthesis, Characterization, and Cytotoxicity of a Novel Highly Charged Trinuclear Platinum Compound. Enhancement of Cellular Uptake with Charge
2005
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal
1996
Two-Photon Oxygen Sensing with Quantum Dot-Porphyrin Conjugates
2013 StandoutNobel
Hypoxia-inducible Factor-1 Mediates Transcriptional Activation of the Heme Oxygenase-1 Gene in Response to Hypoxia
1997 StandoutNobel
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
1993
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
The Biology of Vascular Endothelial Growth Factor
1997 Standout
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Platinum Complexes Can Inhibit Matrix Metalloproteinase Activity: Platinum−Diethyl[(methylsulfinyl)methyl]phosphonate Complexes as Inhibitors of Matrix Metalloproteinases 2, 3, 9, and 12
2007
Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substrates
2009
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.
1989 Standout
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
1999
Tumor heterogeneity: biological implications and therapeutic consequences
1983
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells.
1994
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
Two-Photon Absorbing Nanocrystal Sensors for Ratiometric Detection of Oxygen
2009 StandoutNobel
Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1
1999 StandoutNobel
Hypoxia and radiation response in human tumors
1996
Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
1992
New Therapies for Ovarian Cancer
1992
Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response.
1991
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B
1994
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
1994
Synthesis and in Vitro Antitumor Activity of Platinum Acetonimine Complexes
2006
The current status of new platinum analogs.
1992
Works of J Siracký being referenced
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
1993
The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs
1990
Variation of vascular density within and between tumors of the uterine cervix and its predictive value for radiotherapy
1989
Vascular density in carcinoma of the uterine cervix and its predictive value for radiotherapy
1988
Cytotoxic interactions of Zn2+ in vitro: melanoma cells are more susceptible than melanocytes
1997
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes
1989
The effect of anemia on the radiotherapy results of the uterine cervix cancer.
1975
Prognostic significance of vascular density and a malignancy grading in radiation treated uterine cervix carcinoma.
1988
An approach to the problem of heterogeneity of human tumour-cell populations
1979
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
1991
Relationship between estradiol blood levels and karyopyknotic index (KPI) values in uterine cervical cancer
1980
Vascularization and radiocurability in cancer of the uterine cervix. A retrospective study.
1982